

Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI

NCT06376630

Status	RECRUITING
Phase	Not Applicable
Sponsor	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (6)

- Substudy evaluating cardioprotective effects of early iv administration of esmolol
 - Diagnosed acute ST elevation MI, type 1, within the first 8 hours of disease onset;
 - Treating physician's decision not to administer metoprolol intravenously prior to primary PCI due to a high risk of complications (BP \leq 120/80 mm Hg at baseline examination, moderate evidence of heart failure (Killip 2) or a risk of its development (LV EF \leq 30%), first degree AV block with PQ \leq 0.25 ms, history of asthma or severe COPD etc.)
 - Signed Informed Consent to participate in the study
 - Diagnosed MI, completed PCI for the IRA and multivessel Coronary Artery Disease with diameter stenosis of 50-85% in non-IRA.
- ... and 1 more (see full listing online)

Exclusion (29)

- severe heart failure (pulmonary edema; SCAI -cardiogenic shock);
 - atrioventricular conduction abnormality higher than first degree, without a pacemaker;
 - sinus bradycardia with the heart rate of \leq 60 bpm;
 - BP \leq 100/60 mm Hg.;
 - asthma in exacerbation;
- ... and 24 more (see full listing online)

Locations (1 total)

NMRCCardiologyRu, Moscow, Russia